Results 21 to 30 of about 90,077 (217)

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model

Frontiers in Oncology, 2020
Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer, Catherine Olesch, Annika F. Fink, Matthias Berkefeld, Arnaud Huard, Tobias Schmid, Kazuhiko Takeda, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Andreas Weigert, Andreas Weigert, Andreas Weigert   +13 more
doaj   +1 more source

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma

Cells, 2021
The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane   +3 more
doaj   +1 more source

DISSECTION OF T CELL ACTIVATION PHASES FOR CHECK POINT BLOCKADE IMMUNOTHERAPY

Sabiad, 2022
Checkpoint blockade immunotherapy relies on the restoration of effector responses in precursor-exhausted T cells. Nevertheless, many inhibitory receptors are upregulated soon after the activation and reach high levels at effector phases.
Güneş Esendağlı
doaj   +1 more source

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade

iScience, 2020
Summary: Interleukin-34 (IL-34) is an alternative ligand to colony-stimulating factor-1 (CSF-1) for the CSF-1 receptor that acts as a key regulator of monocyte/macrophage lineage.
Naoki Hama, Takuto Kobayashi, Nanumi Han, Fumihito Kitagawa, Nabeel Kajihara, Ryo Otsuka, Haruka Wada, Hee-kyung Lee, Hwanseok Rhee, Yoshinori Hasegawa, Hideo Yagita, Muhammad Baghdadi, Ken-ichiro Seino   +12 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

Three phosphatase families form a community: The phosphohydrolases that act upon inositol pyrophosphates

FEBS Letters, EarlyView.
Inositol pyrophosphates are energy‐rich signaling molecules that perform critical functions in cells. Three different families of phosphatases hydrolyze the β phosphate of the inositol pyrophosphate molecules: two have narrow specificities and one is promiscuous.
Ronda J. Rolfes
wiley   +1 more source

A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm

Molecular Oncology
Immune checkpoint blockade has emerged as a potent new tool in the war on cancer. However, only a subset of cancer patients benefit from this therapeutic modality, sparking a search for combination therapies to increase the fraction of responding ...
Mary C. Clark, Rongze Olivia Lu, Winson S. Ho, Matheus Henrique Dias, René Bernards, Stephen J. Forman   +5 more
doaj   +1 more source